Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,060mg/0,015mg - gestoden a ethinylestradiol

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateron acetátu - prostatetické novotvary - endokrinní terapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetátu - prostatetické novotvary - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Evropská unie - čeština - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetátu - prostatetické novotvary - endokrinní terapie - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

teva b.v., haarlem array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 19572 abirateron-acetÁt - tableta - 250mg - abirateron

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glenmark pharmaceuticals s.r.o., praha array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach rakousko - 19572 abirateron-acetÁt - tableta - 250mg - abirateron

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron